Persistence of lymphocyte function perturbations after granulocyte–colony‐stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors

BACKGROUND: The short‐term effects of granulocyte–colony‐stimulating factor (G‐CSF) have been extensively studied, but recent reports of G‐CSF–induced genetic perturbations raised concerns regarding its long‐term safety. In this respect, duration of G‐CSF–induced perturbations has been less studied than short‐term effects and needs to be evaluated.

[1]  J. Pallandre,et al.  G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. , 2010, Blood.

[2]  C. Bennett,et al.  Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project , 2007, Bone Marrow Transplantation.

[3]  T. Holyoake,et al.  Immature monocytes from G‐CSF‐mobilized peripheral blood stem cell collections carry surface‐bound IL‐10 and have the potential to modulate alloreactivity , 2006, Journal of leukocyte biology.

[4]  Giuseppe Leone,et al.  Tolerogenic dendritic cells: cytokine modulation comes of age. , 2006, Blood.

[5]  A. Foussat,et al.  Enhanced Frequency of CD18- and CD49b-Expressing T Cells in Peripheral Blood of Asthmatic Patients Correlates with Disease Severity , 2006, International Archives of Allergy and Immunology.

[6]  P. Tazzari,et al.  Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study , 2005, Bone Marrow Transplantation.

[7]  T. Papayannopoulou.  Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. , 2004, Blood.

[8]  A. Nagler,et al.  Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. , 2004, Experimental hematology.

[9]  L. Trakhtenbrot,et al.  Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF , 2003, Bone Marrow Transplantation.

[10]  S. Rutella,et al.  Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. , 2002, Blood.

[11]  D. Blaise,et al.  Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. , 2002, Blood.

[12]  N. Russell,et al.  Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. , 2002, Experimental hematology.

[13]  D. Blaise,et al.  Enhanced activation of B cells in a granulocyte colony‐stimulating factor‐mobilized peripheral blood stem cell graft , 2001, British journal of haematology.

[14]  D. Blaise,et al.  Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. , 2001, Blood.

[15]  T. Fest,et al.  Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. , 2001, Experimental hematology.

[16]  M. Harada,et al.  G-CSF reduces IFN-γ and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function , 2000, Bone Marrow Transplantation.

[17]  D. Maloney,et al.  Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. , 2000, Blood.

[18]  S. Heimfeld,et al.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. , 2000, Blood.

[19]  N. Young,et al.  Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. , 2000, Blood.

[20]  R. Storb,et al.  Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor , 2000, Bone Marrow Transplantation.

[21]  T. Standiford,et al.  CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. , 1999, Journal of immunology.

[22]  T. Hartung,et al.  Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions , 1999, Clinical pharmacology and therapeutics.

[23]  K. Ino,et al.  Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products , 1999, Bone Marrow Transplantation.

[24]  J. Talmadge,et al.  IL‐2 Expansion of T and NK Cells from Growth Factor‐Mobilized Peripheral Blood Stem Cell Products: Monocyte Inhibition , 1998, Journal of immunotherapy.

[25]  F. Re,et al.  Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells , 1998, Bone Marrow Transplantation.

[26]  M. Mielcarek,et al.  Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. , 1998, Blood.

[27]  F. Prósper,et al.  Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. , 1997, Blood.

[28]  D. Stroncek,et al.  Blood counts in healthy donors 1 year after the collection of granulocyte–colony‐stimulating factor‐mobilized progenitor cells and the results of a second mobilization and collection , 1997, Transfusion.

[29]  M. Mielcarek,et al.  Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. , 1997, Blood.

[30]  B. Andersson,et al.  Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. , 1996, Bone marrow transplantation.

[31]  P. Anderlini,et al.  Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.

[32]  E. Montserrat,et al.  Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects [letter; comment] [see comments] , 1996 .

[33]  J. Briones,et al.  Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors , 1996, Annals of Hematology.

[34]  E. Montserrat,et al.  Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects. , 1996, Blood.

[35]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[36]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[37]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[38]  T. Miyawaki,et al.  G‐CSF enhances the immunoglobulin generation rather than the proliferation of human B lymphocytes , 1993, European journal of haematology.